Equillium, Inc., formerly Attenuate Biopharmaceuticals, Inc., was incorporated in Delaware on March 16, 2017. The company is a biotechnology innovator dedicated to developing novel therapies for the treatment of severe autoimmune and inflammatory diseases. Its lead drug candidate, EQ504, is a preclinical stage AhR modulator that initially targets ulcerative colitis, in addition to an oral bispecific inhibitor program in the preclinical stage for gastrointestinal indications.
